Search

everythinglearnresearchcommunity

for

Search:↓

A user is considering an extensive hair loss treatment regimen including oral dutasteride, oral minoxidil, topical finasteride, tretinoin, microneedling, keto shampoo, laser comb, and PRP injections. Suggestions include simplifying the routine, possibly increasing minoxidil dosage, and considering alternatives like RU58841, while cautioning against using estrogen due to potential side effects.

KX-826 is undergoing trials for hair loss treatment, showing similar effectiveness between 0.5% and 1.0% dosages, with mild side effects compared to finasteride. Users discuss combining KX-826 with other treatments like minoxidil and clascoterone for better results.

The conversation discusses sourcing pyrilutamide from China for hair loss treatment, highlighting its potency compared to other AR antagonists like bicalutamide and RU58841. The user expresses interest in trying pyrilutamide despite mixed results in clinical trials.

Kx-826 at 0.5% shows limited effectiveness for hair loss, while 1% is more promising but expensive. RU58841 is considered a more feasible option until 1% kx-826 becomes affordable.

A user is considering using RU58841 to treat hair loss and asks if it can be effective for 4-5 years. Some suggest starting with a lower concentration and debate the safety of RU58841 compared to approved drugs like finasteride.

The user is seeking advice on the best treatment for male pattern baldness, diffuse thinning, and retrograde alopecia, comparing the effectiveness of finasteride, RU58841, and dutasteride, and considering whether to add minoxidil or switch to dutasteride or combine treatments. They are currently on finasteride and are contemplating if adding RU58841 or switching to dutasteride is better, and also asking about the comparison between pyrilutamide and RU58841.

The user has been using Minoxidil and finasteride with success and is now trying Dualgen-5R with retinoic acid but without finasteride, along with microneedling. They plan to share results in 5-6 months.

PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.

Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.

The conversation is about a user offering an unopened bottle of KX-826 (0.5%) for hair loss treatment, stating it works well for them. They are selling it at cost without seeking profit.

A European individual planning to go to China is seeking information on how to participate in HMI-115 trials for Androgenetic Alopecia. They've tried contacting Mrs. Yang and Mr. Wang for assistance but haven't received a response.

The user was using 1mg finasteride daily and oral minoxidil 2.5mg daily for two years, then added RU58841 to their routine two months ago and is asking for opinions on any changes in hair growth. They provided progress pictures without dermarolling and maintained consistent lighting for comparison.

The user discussed their experience with hair loss treatments, including finasteride, RU58841, Nizoral, supplements, dermarolling, and minoxidil, which caused significant edema. They also experimented with dutasteride, which led to increased hair loss, and found that Armodafinil reduced minoxidil-related water retention and hair shedding.

The conclusion of the conversation is that the user, djamezz, has experienced significant regrowth and improved density in their hairline by using treatments such as RU (RU58841), dut (dutasteride), and Inkey's Caffeine Scalp treatment. They are satisfied with their progress and do not plan to cut off their hair.

People are discussing ordering pyrilutamide for hair loss treatment in the US. The treatment is from Kintor's subsidiary company and is available on Amazon.

GHK-Cu is a potent inhibitor of the type 1 5-alpha reductase enzyme in hair follicles, which may reduce hair loss without the side effects associated with type 2 5-alpha reductase inhibitors. The user previously experienced side effects with 5-alpha reductase inhibitors and is considering GHK-Cu as an alternative.

The user is seeking an alternative to DualGen 15 that includes Minoxidil and Retinol but is less sticky and more convenient to use. They find the current product inconvenient due to its stickiness and long wait time before washing.

The user has been using oral minoxidil and dutasteride for hair loss without success and is considering adding topical 17α-estradiol, Pyrilutamide, Clascoterone, or cetirizine. They have confirmed low serum DHT levels and are exploring additional treatments due to genetic sensitivity to DHT and prostaglandin D2.

The user noticed slight hair loss after switching to Milpharm finasteride and is considering switching to Accord finasteride. They seek advice on whether to continue with Milpharm or switch brands.

The conversation is about the availability of Koshine826 PRO 1% for hair loss treatment. The discussion includes Minoxidil, finasteride, and RU58841.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. PP405 is still under evaluation for safety.

The conversation is about the timeline for Kintor's phase 3 trials for GT20029 and the potential release of the product in three years. It also mentions treatments like Minoxidil, finasteride, and RU58841.

The user is currently using finasteride and minoxidil and is considering adding microneedling and either RU58841 or Pyrilutamide for potential hair regrowth. They previously used microneedling, RU58841, and oral minoxidil before their hair transplant.

The conversation discusses hair loss treatments, with the original poster considering joining a clinical trial for setipiprant after experiencing side effects from finasteride and disinterest in minoxidil. Some users express skepticism about setipiprant's effectiveness, while others encourage participation in the trial for potential benefits.

There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.

The conversation discusses the ineffectiveness of dutasteride in halting hair loss for the user and explores the potential of PP405, which works through a different mechanism. Suggestions include considering a biopsy to determine the cause of hair loss and exploring other treatments like RU58841.

Obtaining treatments for hair loss that are not approved in one's own country, such as pyrilutamide or GT20029. It was suggested to use a middleman to get it, but there is the risk of getting low quality or fake products.

The conversation is about a person's one-year progress using finasteride and minoxidil for hair loss, with intermittent use of RU58841, showing improved hair quality, density, and thickness without side effects. Users complimented the improved appearance and suggested the longer hair also enhanced their look.

Pyrilutamide/KX-826 is being considered as a potential treatment for female androgenetic alopecia (AGA), but its high cost and limited data on effectiveness are concerns. Kintor markets it for both men and women.

PP405 is a potential hair loss treatment that may activate dormant hair follicles, but there are concerns about its effectiveness, cost, and side effects. Users discuss treatments like minoxidil, finasteride, and RU58841, expressing skepticism about PP405's long-term success and accessibility.